GI Dynamics’ EndoBarrier non-surgical type 2 diabetes therapy receives CE mark approval
GI Dynamics has announced that it has received European CE mark approval for the EndoBarrier(TM) a non-surgical therapy to treat type 2 diabetes and obesity. The CE marking certifies that a product has met EU requirements for marketing in Europe. Clinical trials involving more than 270 patients have demonstrated the significant weight loss and diabetes improvement achieved with the EndoBarrier Gastrointestinal Liner.
For the full story, Click Here
- Cryolife’s BioGlue receives CE Mark approval
- St Jude Medical receives FDA and CE Mark approval for Strada Carotid Guiding Sheath
- Subscribe
- Virtual Ports EndoGrab device receives CE Mark
